amitriptyline (Q58397)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

medicine used to treat cyclic vomiting syndrome (CVS), depression and a variety of pain syndromes

amitryptiline
5-(gamma-dimethylaminopropylidene)-5H-dibenzo[a,d][1,4]cycloheptadiene
3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethylpropan-1-amine
5-(3-dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene
5-(3-dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptatriene
10,11-dihydro-N,N-dimethyl-5H-dibenzo(a,d)heptalene-delta(5),gamma-propylamine
10,11-dihydro-5-(gamma-dimethylaminopropylidene)-5H-dibenzo[a,d]cycloheptene
10,11-dihydro-N,N-dimethyl-5H-dibenzo[a,d]heptalene-delta(5),gamma-propylamine
3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine

Sprache	Label	Description	Also known as
Englisch	amitriptyline	medicine used to treat cyclic vomiting syndrome (CVS), depression and a variety of pain syndromes	amitryptiline 5-(gamma-dimethylaminopropylidene)-5H-dibenzo[a,d][1,4]cycloheptadiene 3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethylpropan-1-amine 5-(3-dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene 5-(3-dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptatriene 10,11-dihydro-N,N-dimethyl-5H-dibenzo(a,d)heptalene-delta(5),gamma-propylamine 10,11-dihydro-5-(gamma-dimethylaminopropylidene)-5H-dibenzo[a,d]cycloheptene 10,11-dihydro-N,N-dimethyl-5H-dibenzo[a,d]heptalene-delta(5),gamma-propylamine 3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine

Statements

type of chemical entity

0 references

dibenzocycloheptene

1 reference

based on heuristic

inferred from SMILES

0 references

chemical structure

Amitriptyline.svg
211 × 230; 11 KB

0 references

image of molecular model or crystal lattice model

Amitriptyline-from-picrate-xtal-3D-vdW.png
1,100 × 882; 186 KB

space-filling model

0 references

277.183 dalton

1 reference

language of work or name

amitriptyline (English)

17 November 2016

chemical formula

C₂₀H₂₃N

1 reference

language of work or name

amitriptyline (English)

17 November 2016

canonical SMILES

CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31

1 reference

language of work or name

amitriptyline (English)

17 November 2016

defined daily dose

75 milligram

route of administration

oral administration

1 reference

https://www.whocc.no/atc_ddd_index/?code=N06AA09

75 milligram

route of administration

parenteral route of administration

1 reference

https://www.whocc.no/atc_ddd_index/?code=N06AA09

active ingredient in

1 reference

14 February 2018

World Health Organisation international non-proprietary name

amitriptyline (English)

1 reference

language of work or name

Amitriptyline (English)

19 January 2016

medical condition treated

1 reference

language of work or name

13 December 2016

neurotic disorder

1 reference

language of work or name

13 December 2016

1 reference

Drug Indications Extracted from FAERS

2 October 2018

1 reference

Drug Indications Extracted from FAERS

2 October 2018

1 reference

Drug Indications Extracted from FAERS

2 October 2018

significant drug interaction

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

tranylcypromine

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-fenoprofen

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(+-)-flurbiprofen

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-ketoprofen

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-citalopram

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

toxic encephalopathy

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

torsades de pointes

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

pulseless electrical activity

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

torsades de pointes

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

pulseless electrical activity

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

torsades de pointes

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

pulseless electrical activity

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

torsades de pointes

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

pulseless electrical activity

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

torsades de pointes

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

pulseless electrical activity

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(±)-promethazine

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-citalopram

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-hydroxyzine

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

torsades de pointes

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

chlorpheniramine

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

chlorpheniramine

mental status change

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

chlorpheniramine

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

chlorpheniramine

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

mental status change

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-fenoprofen

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(+-)-flurbiprofen

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-ketoprofen

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

heart arrhythmia

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

heart arrhythmia

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

orthostatic hypotension

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

heart arrhythmia

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

cognitive disorder

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

central respiratory depression

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

increased systemic arterial blood pressure

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

toxic encephalopathy

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

mental status change

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

toxic encephalopathy

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

mental status change

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

urinary retention

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

physically interacts with

5-hydroxytryptamine receptor 6

subject has role

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

language of work or name

17 August 2016

5-hydroxytryptamine (serotonin) receptor 7

subject has role

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

language of work or name

17 August 2016

Histamine receptor H1

subject has role

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

language of work or name

17 August 2016

Potassium inwardly-rectifying channel, subfamily J, member 6

subject has role

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

language of work or name

17 August 2016

Potassium inwardly-rectifying channel, subfamily J, member 5

subject has role

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

language of work or name

17 August 2016

Cholinergic receptor muscarinic 1

subject has role

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

language of work or name

17 August 2016

Cholinergic receptor muscarinic 2

subject has role

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

language of work or name

17 August 2016

Cholinergic receptor muscarinic 3

subject has role

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

language of work or name

17 August 2016

Cholinergic receptor muscarinic 4

subject has role

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

language of work or name

17 August 2016

Cholinergic receptor muscarinic 5

subject has role

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

language of work or name

17 August 2016

Solute carrier family 6 member 2

subject has role

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

language of work or name

17 August 2016

solute carrier family 6 member 4

subject has role

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

language of work or name

17 August 2016

route of administration

oral administration

1 reference

imported from Wikimedia project

Russian Wikipedia

Wikimedia import URL

https://ru.wikipedia.org/?oldid=120596366

intramuscular injection

1 reference

imported from Wikimedia project

Russian Wikipedia

Wikimedia import URL

https://ru.wikipedia.org/?oldid=120596366

intravenous infusion and defusion

1 reference

imported from Wikimedia project

Russian Wikipedia

Wikimedia import URL

https://ru.wikipedia.org/?oldid=120596366

legal status (medicine)

1 reference

https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/343802

FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links. (English)

pregnancy category

Australian pregnancy category C

1 reference

imported from Wikimedia project

English Wikipedia

US pregnancy category C

1 reference

imported from Wikimedia project

English Wikipedia

LiverTox likelihood score

LiverTox toxicity likelihood category B

1 reference

8 April 2021

https://www.ncbi.nlm.nih.gov/books/n/livertox/Amitriptyline

1 March 2016

subject has role

selective serotonin reuptake inhibitor

1 reference

5 March 2018

adrenergic uptake inhibitors

2 references

5 March 2018

Medical Subject Headings

MeSH descriptor ID

15 March 2018

non-opioid analgesic

1 reference

Medical Subject Headings

MeSH descriptor ID

15 March 2018

tricyclic antidepressant

1 reference

Medical Subject Headings

MeSH descriptor ID

15 March 2018

essential medicine

0 references

0 references

Commons category

Amitriptyline

0 references

Identifiers

InChI=1S/C20H23N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-12H,7,13-15H2,1-2H3

1 reference

language of work or name

amitriptyline (English)

17 November 2016

KRMDCWKBEZIMAB-UHFFFAOYSA-N

2 references

language of work or name

amitriptyline (English)

17 November 2016

ChEBI release 2020-09-01

CAS Registry Number

2 references

Global Substance Registration System

language of work or name

amitriptyline (English)

17 November 2016

KRMDCWKBEZIMAB-UHFFFAOYSA-N

CAS Common Chemistry

10 April 2021

https://commonchemistry.cas.org/detail?cas_rn=50-48-6

1 reference

language of work or name

Amitriptyline (English)

17 November 2016

2 references

language of work or name

amitriptyline (English)

17 November 2016

matched by identifier from

KRMDCWKBEZIMAB-UHFFFAOYSA-N

Reaxys registry number

2217885

1 reference

language of work or name

amitriptyline (English)

19 October 2016

mapping relation type

2 references

language of work or name

AMITRIPTYLINE (English)

17 November 2016

matched by identifier from

International Chemical Identifier

InChI=1S/C20H23N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-12H,7,13-15H2,1-2H3

1 reference

language of work or name

AMITRIPTYLINE (English)

17 November 2016

2 references

based on heuristic

inferred from InChIKey

matched by identifier from

KRMDCWKBEZIMAB-UHFFFAOYSA-N

UniChem compound ID

1 reference

MassBank accession ID

0 references

MSBNK-Athens_Univ-AU150406

0 references

MSBNK-Eawag-EA282101

0 references

MSBNK-Eawag-EA282102

0 references

MSBNK-Eawag-EA282103

0 references

MSBNK-Eawag-EA282104

0 references

MSBNK-Eawag-EA282105

0 references

MSBNK-Eawag-EA282106

0 references

MSBNK-Eawag-EA282107

0 references

MSBNK-Eawag-EA282108

0 references

MSBNK-Eawag-EA282109

0 references

MSBNK-Eawag-EA282110

0 references

MSBNK-Eawag-EA282111

0 references

MSBNK-Eawag-EA282112

0 references

MSBNK-Eawag-EA282113

0 references

MSBNK-Eawag-EA282114

0 references

MSBNK-Fiocruz-FIO00473

0 references

MSBNK-Fiocruz-FIO00474

0 references

MSBNK-Fiocruz-FIO00475

0 references

MSBNK-Fiocruz-FIO00476

0 references

MSBNK-Fiocruz-FIO00477

0 references

MSBNK-Fac_Eng_Univ_Tokyo-JP003854

0 references

MSBNK-Waters-WA000917

0 references

MSBNK-Waters-WA000918

0 references

MSBNK-Waters-WA000919

0 references

MSBNK-Waters-WA000920

0 references

MSBNK-Waters-WA000921

0 references

splash10-001i-1590000000-35080e23f36a6ed30005

0 references

splash10-004i-0090000000-66d4e2dc0e65719c8949

0 references

splash10-004i-0190000000-18fad36e219aa0091dcf

0 references

splash10-05o3-3980000000-bd3bb65e31837e45268f

0 references

splash10-0aou-2940000000-c3c71a4ddeb15eb427b4

0 references

splash10-05mo-2930000000-f6bc4a5899aed7b3047e

0 references

splash10-0fr6-2930000000-c348567e54820b6ddff3

0 references

splash10-004i-0090000000-fae7f4e9cc1f20e9a2dd

0 references

splash10-004i-0190000000-42ecf4fcfbd4bd102322

0 references

splash10-05o3-3980000000-69e1e5d2fdd46de25ba4

0 references

splash10-0aou-2940000000-853a0f18213b600d48ae

0 references

splash10-05mo-2930000000-9493535ee63a9a708527

0 references

splash10-0fr6-2930000000-fba97ca65c4bf1940385

0 references

splash10-001i-1690000000-99ea606fc86c8400c4ce

0 references

splash10-0a4i-9010000000-2afae55587735e5a8ce1

0 references

splash10-004i-0090000000-8155764b5e04e44b4ca2

0 references

splash10-004i-0190000000-7e3a5d063f540759d63f

0 references

splash10-0apl-0960000000-e35715828f4c02816f19

0 references

splash10-0lfu-0940000000-a6befd2c2f6b01d0c348

0 references

splash10-0v03-0940000000-cab5377d28cf5d892f47

0 references

splash10-004i-2590000000-85fb81c2565771c07a12

0 references

splash10-0a4i-9210000000-989cd234a8cdf04c5f69

0 references

1 reference

Hazardous Substances Data Bank

publication date

28 October 2019

AMITRIPTYLINE (English)

10 May 2021

DSSTox substance ID

2 references

Mapping file of InChIStrings, InChIKeys and DTXSIDs for the EPA CompTox Dashboard

matched by identifier from

KRMDCWKBEZIMAB-UHFFFAOYSA-N

DSSTOX compound identifier

0 references

0 references

200-041-6

1 reference

Global Substance Registration System

language of work or name

amitriptyline (English)

17 November 2016

ECHA Substance Infocard ID

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

27 December 2018

Amitriptyline (English)

CAS no.: 50-48-6 (English)

1 reference

language of work or name

Amitriptyline (English)

publication date

17 November 2015

Guide to Pharmacology Ligand ID

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

language of work or name

amitriptyline (English)

17 November 2016

MeSH descriptor ID

subject named as

Amitriptyline

0 references

D02.455.426.559.847.181.384.100

0 references

D04.615.181.384.100

0 references

1 reference

Global Substance Registration System

language of work or name

amitriptyline (English)

17 November 2016

1 reference

matched by identifier from

KRMDCWKBEZIMAB-UHFFFAOYSA-N

Human Metabolome Database ID

2 references

based on heuristic

inferred from InChIKey

matched by identifier from

KRMDCWKBEZIMAB-UHFFFAOYSA-N

2 references

Global Substance Registration System

language of work or name

amitriptyline (English)

17 November 2016

matched by identifier from

KRMDCWKBEZIMAB-UHFFFAOYSA-N

MedlinePlus drug identifier

0 references

PatientsLikeMe treatment ID

0 references

1 reference

Global Substance Registration System

language of work or name

amitriptyline (English)

17 November 2016

Probes And Drugs ID

0 references

1 reference

1 reference

language of work or name

amitriptyline (English)

19 October 2016

1 reference

language of work or name

amitriptyline (English)

19 October 2016

0 references

0 references

electronic Essential Medicines List medicine ID

0 references

Encyclopædia Britannica Online ID

science/amitriptyline

subject named as

amitriptyline

0 references

1 reference

Freebase Data Dumps

publication date

28 October 2013

Gran Enciclopèdia Catalana ID

0 references

Gran Enciclopèdia Catalana ID (former scheme)

0 references

1 reference

9 July 2020

Microsoft Academic ID

0 references

1 reference

26 January 2022

https://docs.openalex.org/download-snapshot/snapshot-data-format

PDB structure ID

1 reference

Protein Data Bank

PDB structure ID

language of work or name

3APV (English)

19 October 2016

1 reference

Protein Data Bank

PDB structure ID

language of work or name

5HA9 (English)

19 October 2016

Amitriptyline-1

1 reference

1 reference

Global Substance Registration System

language of work or name

amitriptyline (English)

17 November 2016

WikiProjectMed ID

0 references

Wolfram Language entity code

Entity["Concept", "Amitriptyline::dpg47"]

0 references

WordNet 3.1 Synset ID

02705434-n

1 reference

Sitelinks

Wikipedia(42 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(1 entry)

commonswiki Category:Amitriptyline

Retrieved from "https://www.wikidata.org/w/index.php?title=Q58397&oldid=2188114618"